Agomab Therapeutics (AGMB) CEO details option and share holdings

Rhea-AI Filing Summary

Agomab Therapeutics NV director and Chief Executive Officer Tim Jasper Knotnerus filed an initial ownership report showing his equity position in the company. The filing lists multiple stock options to buy common shares with exercise prices of $1.1300, $0.0005 and $14.2600, expiring between 2029 and 2036. Some options are fully vested and exercisable, while others vest over time based on continued service. He also reports holding 10,823 common shares directly and 34,394 common shares indirectly through TJK Life Sciences B.V., over which he has voting and dispositive power but disclaims beneficial ownership except for any pecuniary interest.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Knotnerus Tim Jasper

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares(1)	10,823	D
Common shares(1)	34,394	I	By TJK Life Sciences B.V.(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(3)	03/14/2029	Common shares(1)	58,918	$1.13(4)	D
Stock Option (Right to Buy)	(3)	10/09/2029	Common shares(1)	43,853	$1.13(4)	D
Stock Option (Right to Buy)	(3)	04/17/2030	Common shares(1)	37,144	$1.13(4)	D
Stock Option (Right to Buy)	(3)	10/30/2030	Common shares(1)	83,507	$1.13(4)	D
Stock Option (Right to Buy)	(3)	03/05/2031	Common shares(1)	308,875	$0.0005(4)	D
Stock Option (Right to Buy)	(3)	06/28/2032	Common shares(1)	104,394	$0.0005(4)	D
Stock Option (Right to Buy)	(3)	10/10/2033	Common shares(1)	307,793	$0.0005(4)	D
Stock Option (Right to Buy)	(5)	07/08/2034	Common shares(1)	18,875	$0.0005(4)	D
Stock Option (Right to Buy)	(5)	11/04/2034	Common shares(1)	683,248	$0.0005(4)	D
Stock Option (Right to Buy)	(6)	01/15/2036	Common shares(1)	436,268	$14.26(4)	D

Explanation of Responses:

1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

2. Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

3. The shares underlying this option are fully vested and exercisable.

4. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

5. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

6. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing for Agomab Therapeutics (AGMB) show for CEO Tim Knotnerus?

The Form 3 shows CEO Tim Jasper Knotnerus’ initial ownership in Agomab Therapeutics. It details his direct and indirect common share holdings and several stock option awards with different exercise prices and expiration dates, outlining his current equity-based stake in the company.

How many Agomab Therapeutics (AGMB) common shares does the CEO hold directly and indirectly?

Tim Knotnerus reports holding 10,823 common shares directly and 34,394 common shares indirectly via TJK Life Sciences B.V. He exercises voting and dispositive power over the indirect shares but disclaims beneficial ownership except for any pecuniary interest he may have.

What stock options are reported by the Agomab Therapeutics (AGMB) CEO in this Form 3?

The CEO reports multiple stock options to buy common shares with exercise prices of $1.1300, $0.0005 and $14.2600. These options have expiration dates ranging from 2029 through 2036, reflecting a mix of fully vested and time-vesting grants.

Are any of the Agomab Therapeutics (AGMB) CEO’s options fully vested and exercisable?

Yes. A footnote states that the shares underlying at least one option are fully vested and exercisable. Other options follow vesting schedules with portions vesting immediately and the remainder in equal monthly installments, contingent on his continued service with the company.

How are the Agomab Therapeutics (AGMB) CEO’s indirect holdings structured?

Indirect holdings consist of 34,394 common shares held by TJK Life Sciences B.V. The CEO has voting and dispositive power over these shares but expressly disclaims beneficial ownership for Section 16 purposes, except to the extent of any pecuniary interest he might have.

Can Agomab Therapeutics (AGMB) common shares be held as American Depositary Shares (ADS)?

Yes. A footnote explains that common shares may be represented by American Depositary Shares, with each ADS currently representing one common share. This structure allows investors to hold exposure to Agomab’s equity through ADS listed in U.S. markets.

How were the Agomab Therapeutics (AGMB) option exercise prices determined in the Form 3?

The filing notes that exercise prices are reported in U.S. dollars after converting from euros using an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026, ensuring consistent currency presentation across the reported option grants.